School of Medicine, University of Queensland, Australia
Chris obtained his PhD from the University of Queensland. The topic of his PhD was to explore the therapeutic potential of nuclear factor kappa B inhibition in renal cell carcinoma (kidney cancer). He has extensive industry experience in monitoring Phase I-III clinical trials. His main research interests are kidney cancer and end stage kidney disease. Current projects include identification of novel biomarkers for kidney cancer, molecular mechanisms of drug resistance in kidney cancer and proteinuria-induced end stage kidney disease.
Medicinal Chemistry received 6627 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 